Flavoprotein oxidoreductase

Flavoprotein oxidoreductases are a vast and diverse class of enzymes characterized by the presence of a flavin nucleotide cofactor, either flavin mononucleotide (FMN) or flavin adenine dinucleotide (FAD) [1]. These enzymes are essential for a wide array of redox reactions in cellular metabolism, including the mitochondrial electron transport chain, fatty acid beta-oxidation, and the degradation of neurotransmitters [2]. Due to their central role in maintaining redox homeostasis and energy production, they are implicated in numerous pathologies such as neurodegenerative diseases (e.g., Parkinson's disease via monoamine oxidase), cardiovascular conditions, and cancer [3]. Specific members of this family, such as monoamine oxidase (MAO) and xanthine oxidase, serve as major therapeutic targets for drugs like selegiline and allopurinol [4]. However, the broad distribution and structural conservation of flavin-binding domains across hundreds of human enzymes present significant challenges for drug selectivity and can lead to off-target toxicity [2, 5]. Consequently, therapeutic development requires precise targeting of unique structural features within the specific enzyme's active site to minimize systemic side effects [3].

Other names

FlavoenzymeFlavin-dependent oxidoreductaseFMN/FAD-dependent enzymeFlavin-containing oxidoreductase

Inhibition of enzymatic activity through competitive binding at the substrate site or covalent modification of the flavin cofactor (FMN or FAD).